Not Yet Recruiting
Study to Evaluate the Effect of Rifampin on the Drug Levels in Blood and Safety of BMS-986235 in Healthy Participants - CV018-023
Opdateret:
11 maj, 2020
|
ClinicalTrials.gov
Fase
Køn
Aldersinterval
Beliggenhed(er)
Not Yet Recruiting
For more information regarding Bristol Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Healthy participants, as determined by no clinically significant deviation from normal in physical examination, ECGs, and clinical laboratory determinations; no significant findings in medical history. - Body mass index of 18.0 kg/m2 to 30.0 kg/m2, inclusive, at screening - Males must agree to follow specific methods of contraception, if applicable Exclusion Criteria: - Women of childbearing potential (WOCBP) - Known previous exposure to BMS-986235 - History of any significant drug allergy Other protocol-defined inclusion/exclusion criteria apply
Hvis du vil rapportere en bivirkning, kan du indberette direkte til Lægemiddelstyrelsen via hjemmesiden www.meldenbivirkning.dk
Vi anbefaler at du også kontakter BMS for at rapportere bivirkninger.
Bivirkninger og andre rapporterbare begivenheder er defineret her
Rapporter bivirkninger eller klager over produktkvalitet: Medicinsk information
466-DK-2200001